For those who may not have heard, Innovaderm officially rebranded to Indero on March 7th, 2025. As the Chief Business Officer of Indero, I am excited to share that this change marked a significant milestone in our journey and reflects our commitment to innovation in clinical research.
In this article, I will discuss the reasons behind our rebranding, the approach we have taken, the progress over the past 2 months, and our vision for the future of Indero.
The Why Â
The transition, which coincided with the companyâs 25th anniversary, was driven by the expansion into rheumatology services alongside dermatology. This expansion necessitated rebranding the company, as the market could no longer be approached under the Innovaderm name. After an extensive evaluation of various names, trademarks, and competitive landscapes, the name Indero was chosen. Preparations for this rebranding and launch were underway for over 12 months prior to the announcement.
ApproachÂ
A comprehensive rebranding strategy was developed, involving various internal and external stakeholders. The transition from Innovaderm to Indero aimed to reposition the company in the marketplace without any changes in ownership or mergers. The expansion into a different therapeutic area (rheumatology) necessitated rebranding to ensure market clarity about the companyâs identity and services. Maintaining excellence in scientific rigor and quality remains a priority.
Innovadermâs reputation for understanding the nuances of running dermatology trials is being leveraged in the rheumatology sphere. No other rheumatology focused CROs were found, highlighting an unmet need in the market. The goal is to fill this gap by offering rigorous and expert services in both dermatology and rheumatology.
Progress Since RebrandingÂ
Since the rebranding, we have seen positive responses from both existing and potential clients. Our efforts to communicate the transition effectively have helped maintain brand loyalty and recognition. The core values of providing dermatology and rheumatology services remain unchanged, and our commitment to scientific excellence continues to drive our work. We have successfully attracted new clients, particularly those focused solely on rheumatology, and have leveraged our global capabilities to introduce the Indero brand in Europe, Latin America, and Asia Pacific. The rebranding has provided an opportunity to strengthen our presence globally and expand our reach.
The Vision of InderoÂ
Maintaining the companyâs identity and core values is essential. The commitment to high-quality service must remain intact. Understanding the clinical trial landscape and investigator landscape is key. The approach used in dermatology is being applied to rheumatology, offering a tailored expert approach to both therapeutic areas. We are now a dual-focused CRO, filling a market gap and offering a tailored expert approach to both therapeutic areas. The potential for rapid growth and an expanding reputation in rheumatology is significant. The hard work and effort put into this transition are expected to yield great results, benefiting many companies that previously lacked access to these services.
The rebranding of Innovaderm to Indero represents a pivotal moment in our company’s evolution. By embracing this new identity, we are better positioned to reflect our innovative spirit and commitment to advancing clinical research. Through careful planning and a focus on collaboration, we are actively navigating this transition smoothly, ensuring continued success and impactful results for our clients and partners. As we look to the future, Indero remains dedicated to driving progress in healthcare and improving patient outcomes.
Letâs shape the future of research and make a difference in the industry, gain Inderoâs support in your upcoming trial and propel your study to new heights.
About the AuthorÂ
Jason Shuris
Jason Shuris is the Chief Business Officer at Indero with over 25 years of experience in the healthcare and life sciences industry. Throughout his career, he has demonstrated exceptional leadership and expertise, particularly in the fields of dermatology and ophthalmology. For more than 11 years, Jason has held senior leadership roles at CROs, where he has been instrumental in driving strategic initiatives and fostering innovation. In addition to his leadership roles, Jason has over 5 yearsâ experience in finance positions at prominent biotech companies based in Boston. His financial acumen and strategic insights have been pivotal in guiding these companies through various stages of growth and development.
